PF-08046054/SGN-PDL1V
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for PF-08046054/SGN-PDL1V, covering 2026-04-20 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) [Phase 3]